| 1 |
Review Safety and efficacy of neonatal vaccination. 2009
Demirjian A, Levy O. · Department of Medicine, Division of Infectious Diseases, Children's Hospital Boston, Boston, MA 02115, USA. · Eur J Immunol. · Pubmed #19089811 No free full text.
Abstract: Newborns have an immature immune system that renders them at high risk for infection while simultaneously reducing responses to most vaccines, thereby posing challenges in protecting this vulnerable population. Nevertheless, certain vaccines, such as BCG and Hepatitis B vaccine, do demonstrate safety and some efficacy at birth, providing proof of principal that certain antigen-adjuvant combinations are able to elicit protective neonatal responses. Moreover, birth is a major point of healthcare contact globally meaning that effective neonatal vaccines achieve high population penetration. Given the potentially significant benefit of vaccinating at birth, availability of a broader range of more effective neonatal vaccines is an unmet medical need and a public health priority. This review focuses on safety and efficacy of neonatal vaccination in humans as well as recent research employing novel approaches to enhance the efficacy of neonatal vaccination.
|
| 2 |
Minor Novel vaccines: bridging research, development and production. 2008
Demirjian A, Levy O. · Department of Medicine, Division of Infectious Diseases, Children's Hospital, Boston, MA 02115, USA. · Expert Rev Vaccines. · Pubmed #18980535 No free full text.
Abstract: Vaccines are among the greatest achievements of modern medicine, leading to the eradication of naturally occurring smallpox, the near elimination of polio and the control of diseases such as rotavirus and hepatitis A and B in industrialized countries. Conventional vaccines, however, protect against a limited number of infectious diseases and, in some cases, provide incomplete protection. Effective vaccines against common infections such as HIV, hepatitis C and malaria remain an unmet medical need. These gaps, together with the threat of resurgence of eradicated diseases, contribute to the growing need for the development of new vaccines and the improvement of existing ones. Approximately 250 scientists and vaccine experts from around the world gathered at Cambridge Healthtech Institute's 3rd Annual Immunotherapeutics and Vaccine Summit (ImVacS 2008) to present the latest developments in this field and to discuss, in 64 presentations, the challenges and current approaches to development and production of novel vaccines.
|
|
|